SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) Receivables

The latest receivables for BCYPU is $1.5M as of September 2026. That compares with $560K in the prior-year period — up 168.6% year over year. Investors often review this figure alongside SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, BCYPU's receivables moved from $560K to $1.5M — a 168.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt)'s operating scale or balance-sheet position.

A receivables figure of $1.5M for BCYPU is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BCYPU's receivables ($1.5M), review year-over-year change from $560K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.